Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05519683 · ClinicalTrials.gov registry record · Phase 2
Home Transcutaneous Electrical Acustimulation (TEA)
A Phase 2 study of Irritable Bowel Syndrome With Constipation, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT05519683 is a Phase 2 study of Irritable Bowel Syndrome With Constipation that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 160 participants, roughly in line with the 159-participant average among 3 other Irritable Bowel Syndrome With Constipation trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05519683, a Phase 2 study of Irritable Bowel Syndrome With Constipation, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.
Conditions Studied
Interventions
- DEVICE TEA
- DRUG Lexapro
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-11-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05519683
The ClinicalTrials.gov registry entry for NCT05519683 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 159-participant average among 3 other Irritable Bowel Syndrome With Constipation trials with a reported enrollment target. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Irritable Bowel Syndrome With Constipation appearing as the primary indexed condition, and to 2 interventions - of which TEA is the first listed.
NCT05519683 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05519683 about?
NCT05519683 is a clinical study titled "Home Transcutaneous Electrical Acustimulation (TEA)". This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.
What is the current status of trial NCT05519683?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2022-11-02. Estimated completion is 2026-09.
What conditions does trial NCT05519683 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome With Constipation.
What interventions are being tested in trial NCT05519683?
The interventions under investigation include: TEA (DEVICE), Lexapro (DRUG).
Who is sponsoring clinical trial NCT05519683?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05519683 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome With Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.